
Last week’s GenSearch’s roundtable, “ESG, déjà au cœur de la stratégie des Healthtech?”, perfectly aligned with our commitment to share market topics expertise within our network and to promoting sustainable practices across the life sciences, biotech, and Healthtech sectors..
Last week’s GenSearch roundtable, “ESG, déjà au cœur de la stratégie des Healthtech?”, reaffirmed our commitment to thought leadership and sustainable progress within the life sciences, biotech, and Healthtech sectors.
The evening began with an insightful introduction by our CEO, Sébastien Stoitzner, highlighting the ongoing challenges in the early-stage market. The session was expertly moderated by Pauline Rambaud, setting the tone for a practical and forward-looking conversation around embedding ESG (Environmental, Social, and Governance) principles into Healthtech and biotech business models.
Key Insights from the Roundtable
🔹 Aude Kermarrec provided much-needed clarity on ESG-related frameworks—ESG, impact investing, ISR, RSE, and CSRD—and shared how Go Capital is addressing these across diverse sectors.
🔹 Jean-Christophe Marcoux illustrated how Genfit has integrated ESG into its strategy with measurable impact: increased stakeholder trust, strategic clarity, and long-term value creation.
This conversation strongly resonates with us at GenSearch, where sustainability is part of who we are—not a separate initiative. Our EcoVadis Gold rating, earned for the second consecutive year, reflects our dedication to responsible business, ethical leadership, and sustainable growth in the executive search industry for life sciences.
Key Takeaways for Healthtech & Biotech Leaders:
-
ESG is no longer optional. It is becoming a strategic imperative for Healthtech and biotech companies aiming to deliver lasting value.
-
Generic ESG evaluation grids often fall short for Healthtech—so it’s essential to define the elements at the heart of your unique ESG approach.
How is your organisation integrating ESG into its long-term strategy?